|
Liver diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Currently, strong evidence implicates <i>IFNL3/4</i> polymorphisms and interferon (IFN)-λ3 levels as determinants of the extent of hepatic inflammation and fibrosis in viral and nonviral liver diseases, as well as in governing the severity of nonhepatotropic viral diseases.
|
31013168 |
2019 |
|
Liver diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In patients who had advanced liver fibrosis but not HCV-1 infection, factors that had significant independent associations with advanced liver fibrosis included age (OR/CI: 1.039/1.016-1.063, P = .001) and platelet count (OR/CI: 0.99/0.986-0.995, P < .001); additionally, IL-28B genetic variants were not associated with liver disease severity.Unfavorable IL-28B genetic variants were associated with advanced liver disease.
|
29517696 |
2018 |
|
Liver diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The association between IFNL3/4 genotypes with elevated HCV VL observed in HCV g6-infected individuals may have implications for the progression of liver disease in Southeast Asian countries where this viral genotype predominates and therefore warrants further studies.
|
29022122 |
2018 |
|
Liver diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
We aimed to assess whether genotypes of IL-28B can play a role in therapeutic response or advanced stages of liver disease.
|
28214926 |
2017 |
|
Liver diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
HLA and IL-28B genes were independently associated with severity of HCV-related liver disease.
|
27172242 |
2016 |
|
Liver diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Wild type haplotype (TLR2 ins/ins- IL28B C/C) was also found associated with older age in patients with an hepatic diseases (in CIR and in HCC p = 0.038 and p = 0.020, respectively) supporting an effect of innate immunity in the liver disease progression.
|
27183918 |
2016 |
|
Liver diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In patients bearing the IFNL3-TT allele, NK cell effector function correlated with liver disease activity.
|
26034208 |
2015 |
|
Liver diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
This review describes the impact of genetic variants of interleukin 28B (IL28B; also known as interferon-lambda 3), inosine triphosphate pyrophosphatase (ITPA) and patatin-like phospholipase domain-containing 3 (PNPLA3) on therapeutic outcome and liver disease severity in HCV-infected patients.
|
26250055 |
2015 |
|
Liver diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
However, very few data are available about its value in predicting sustained virologic response (SVR) in patients with cirrhosis, and whether IFN-λ3 genotype influences liver disease progression remains unclear.
|
25446338 |
2015 |
|
Liver diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Several genome-wide association studies have revealed that HLA-DP/DQ, STAT4 and IL-28B associated with liver diseases.
|
25041342 |
2015 |
|
Liver diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The major alleles of IL28B (rs12980275 A, rs11881222 A, rs8099917 T, and rs7248668 G) are associated with increased odds of liver disease severity in HIV patients infected with HCV-genotype 3.
|
23103287 |
2013 |
|
Liver diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Relation of IL28B gene polymorphism with biochemical and histological features in hepatitis C virus-induced liver disease.
|
22666430 |
2012 |
|
Liver diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We evaluated, in a unique well-characterized cohort of HCV-4 patients, the association of IL28B polymorphism with response to treatment or liver disease severity.
|
21951981 |
2012 |
|
Liver diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
IL28B genotype prevalence in 170 patients with liver disease in this region of Italy was consistent with data reported in Caucasian populations.
|
21903134 |
2011 |
|
Liver diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Novel findings for the development of drug therapy for various liver diseases: Genetic variation in IL-28B is associated with response to the therapy for chronic hepatitis C.
|
21350308 |
2011 |